目的:评价奥马珠单抗治疗变应性肺曲霉病的临床疗效。方法:用计算机检索CHKI、PubMed、Embase、中华医学期刊全文数据库、万方等数据库,筛选奥马珠单抗治疗变应性肺曲霉病的相关文献,检索时间从建库起至2022年4月,最后采用RevMan15.4软件进行Meta分析。结果:纳入24篇文献进行Meta分析,Meta分析结果表明:应用奥马珠单抗后,嗜酸性粒细胞(MD = −2.85, 95% CI = −5.34~−0.37)、血清中总IgE (MD = −296.62, 95% CI = −481.09~−112.15)以及烟曲霉特异性IgE (MD = −6.00, 95% CI = −6.89~−5.11)的水平较前降低,FEV
1 (MD = −7.93, 95% CI = −4.33~−11.53)水平较前升高。结论:奥马珠单抗可以减轻变应性肺曲霉病患者血清中嗜酸性粒细胞、血清中总IgE以及烟曲霉特异性IgE的水平,升高FEV
1的水平,具有一定的临床疗效,但未来仍需要更多、高质量的随机对照实验进一步研究证实。
Objective: To evaluate the clinical efficacy of omalizumab in the treatment of allergic pulmonary aspergillosis. Methods: CHKI, PubMed, Embase, Chinese Medical Journal Full-text Database, Wan-fang and other databases were searched by computer to screen the relevant literature on omi-zumab in the treatment of allergic pulmonary aspergillosis from the establishment of the database to April 2022. Finally, RevMan15.4 software was used for meta-analysis. Results: 24 articles were included for meta-analysis, and the results showed that: after omizumab administration, eosino-phils (MD = −2.85, 95% CI = −5.34 to −0.37), serum total IgE (MD = −296.62, 95% CI = −481.09 to −112.15) and Aspergillus fumigatus specific IgE (MD = −6.00, 95% CI = −6.89 to −5.11) were de-creased, and the level of FEV
1 (MD = −7.93, 95% CI = −4.33~11.53) was increased. Conclusion: Omizumab can reduce the levels of eosinophils, total IgE and Aspergillus fumigatus specific IgE in serum of patients with allergic pulmonary aspergillosis, and increase the level of FEV
1, which has a certain clinical effect. However, more high-quality randomized controlled trials are still needed to further study and confirm in the future.
Objective: To evaluate the clinical efficacy of omalizumab in the treatment of allergic pulmonary aspergillosis. Methods: CHKI, PubMed, Embase, Chinese Medical Journal Full-text Database, Wanfang and other databases were searched by computer to screen the relevant literature on omizumab in the treatment of allergic pulmonary aspergillosis from the establishment of the database to April 2022. Finally, RevMan15.4 software was used for meta-analysis. Results: 24 articles were included for meta-analysis, and the results showed that: after omizumab administration, eosinophils (MD = −2.85, 95% CI = −5.34 to −0.37), serum total IgE (MD = −296.62, 95% CI = −481.09 to −112.15) and Aspergillus fumigatus specific IgE (MD = −6.00, 95% CI = −6.89 to −5.11) were decreased, and the level of FEV1 (MD = −7.93, 95% CI = −4.33~11.53) was increased. Conclusion: Omizumab can reduce the levels of eosinophils, total IgE and Aspergillus fumigatus specific IgE in serum of patients with allergic pulmonary aspergillosis, and increase the level of FEV1, which has a certain clinical effect. However, more high-quality randomized controlled trials are still needed to further study and confirm in the future.
魏永梅,马俊彦,李 阳,王登本,李东繁. 奥马珠单抗治疗变应性肺曲霉病临床疗效的Meta分析Clinical Efficacy of Omalizumab in the Treatment of Allergic Pulmonary Aspergillosis: A Meta-Analysis[J]. 临床医学进展, 2022, 12(11): 10480-10488. https://doi.org/10.12677/ACM.2022.12111510
参考文献ReferencesAgarwal, R., Sehgal, I.S., Dhooria, S., et al. (2020) Allergic Bronchopulmonary Aspergillosis. Indian Journal of Medi-cal Research, 151, 529-549. <br>https://doi.org/10.4103/ijmr.IJMR_1187_19温林芳, 刘双, 李梅, 徐晓峰, 刘羽佳, 常远. 变应性支气管肺曲霉病的治疗进展[J]. 中华内科杂志, 2019, 58(2): 150-153.Ali, M. and Green, O.N. (2021) Dupilumab: A New Contestant to Corticosteroid in Allergic Bronchopulmonary Aspergillosis. Oxford Medical Case Reports, 2021, omaa029. <br>https://doi.org/10.1093/omcr/omaa029兰天飞, 王学艳, 王洪田. IgE与奥马珠单抗的研究进展[J]. 标记免疫分析与临床[J], 2021, 28(2): 343-347.Zicari, A.M., Celani, C., De Cas-tro, G., Valerio De Biase, R. and Duse, M. (2014) Anti IgE Antibody as Treatment of Allergic Bronchopulmonary As-pergillosis in a Patient with Cystic Fibrosis. European Review for Medical and Pharmacological Sciences, 18, 1839-1841.Mai, K.E. (2012) Management of Patients with Cystic Fibrosis and Allergic Bronchopulmonary As-pergillosis Using Anti-Immunoglobulin E Therapy (Omalizumab). The Journal of Pediatric Pharmacology and Thera-peutics, 17, 88-92.
<br>https://doi.org/10.5863/1551-6776-17.1.88Jacquelyn, M.Z. (2008) Steroid-Sparing Effect of Omalizumab for Allergic Bronchopulmonary Aspergillosis and Cystic Fibrosis. Pediatric Pulmonology, 43, 607-610. <br>https://doi.org/10.1002/ppul.20804肖幸幸, 韩国敬. 奥马珠单抗治疗变应性支气管肺曲霉菌病的临床疗效分析[J]. 临床肺科杂志, 2018, 23(12): 2219-2221.马薇. 奥马珠单抗治疗变应性支气管肺曲霉菌病患者的临床疗效[J]. 中国药物经济学, 2020, 15(12): 87-89+92.Agarwal, R., Chakrabarti, A., Shah, A., et al. (2013) Allergic Bronchopulmonary Aspergillosis: Review of Literature and Proposal of New Diagnostic and Classification Cri-teria. Clinical & Experimental Allergy, 43, 850-873.
<br>https://doi.org/10.1111/cea.12141Ashkenazi, M., Sity, S., Sarouk, I., et al. (2018) Omalizumab in Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis. Journal of Asthma and Allergy, 11, 101-107. <br>https://doi.org/10.2147/JAA.S156049Aydin, O., Sozener, Z.C., Soyyigit, S., et al. (2015) Omalizumab in the Treatment of Allergic Bronchopulmonary Aspergillosis: One Center’s Experience with 14 Cases. Allergy and Asthma Proceedings, 36, 493-500.
<br>https://doi.org/10.2500/aap.2015.36.3909Beam, K.T. and Coop, C.A. (2015) Steroid Sparing Effect of Omalizumab in Seropositive Allergic Bronchopulmonary Aspergillosis. Allergy & Rhinology, 6, 143-145. <br>https://doi.org/10.2500/ar.2015.6.0128Emiralioglu, N., Dogru, D., Tugcu, G.D., et al. (2016) Omalizumab Treatment for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis. Annals of Pharmacotherapy, 50, 188-193. <br>https://doi.org/10.1177/1060028015624204Galera, C., Pur Ozygit, L., Cavigioli, S., Bousquet, P.J. and De-moly, P. (2010) Gadoteridol-Induced Anaphylaxis—Not a Class Allergy. Allergy, 65, 132-134. <br>https://doi.org/10.1111/j.1398-9995.2009.02137.xHomma, T., Kurokawa, M., Matsukura, S., Yamaguchi, M. And Adachi, M. (2016) Anti-IgE Therapy for Allergic Bronchopulmonary Aspergillosis. Journal of Microbiology, Im-munology and Infection, 49, 459-463.
<br>https://doi.org/10.1016/j.jmii.2013.10.003Kanu, A. and Patel, K. (2008) Treatment of Allergic Bronchopul-monary Aspergillosis (ABPA) in CF with Anti-IgE Antibody (Omalizumab). Pediatric Pulmonology, 43, 1249-1251. <br>https://doi.org/10.1002/ppul.20907Koutsokera, A., Corriveau, S., Sykes, J., et al. (2020) Omalizumab for Asthma and Allergic Bronchopulmonary Aspergillosis in Adults with Cystic Fibrosis. Journal of Cystic Fibrosis, 19, 119-124.
<br>https://doi.org/10.1016/j.jcf.2019.07.011Lebecque, P., Leonard, A., Argaz, M., et al. (2009) Omalizumab for Exacerbations of Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis. BMJ Case Reports, 2009, bcr0720080379.
<br>https://doi.org/10.1136/bcr.07.2008.0379Lehmann, S., Pfannenstiel, C., Friedrichs, F., et al. (2014) Omali-zumab: A New Treatment Option for Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis. Thera-peutic Advances in Respiratory Disease, 8, 141-149.
<br>https://doi.org/10.1177/1753465814547517Lin, R.Y., Sethi, S. and Bhargave, G.A. (2010) Measured Immu-noglobulin E in Allergic Bronchopulmonary Aspergillosis Treated with Omalizumab. Journal of Asthma, 47, 942-945. <br>https://doi.org/10.3109/02770903.2010.491144Nathan, N., Girodon, E., Clement, A. and Corvol, H. (2012) A Rare CFTR Intronic Mutation Related to a Mild CF Disease in a 12-Year-Old Girl. BMJ Case Reports, 2012, bcr2012006918. <br>https://doi.org/10.1136/bcr-2012-006918Nove-Josserand, R., Grard, S., Auzou, L., et al. (2017) Case Series of Omalizumab for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis Patients. Pediatric Pulmonology, 52, 190-197. <br>https://doi.org/10.1002/ppul.23612O’reilly, A. and Dunican, E. (2021) The Use of Targeted Monoclonal Antibodies in the Treatment of ABPA-A Case Series. Medicina, 58, Article No. 53. <br>https://doi.org/10.3390/medicina58010053Perisson, C., Destruys, L., Grenet, D., et al. (2017) Omalizumab Treatment for Allergic Bronchopulmonary Aspergillosis in Young Patients with Cystic Fibrosis. Respiratory Medicine, 133, 12-15.
<br>https://doi.org/10.1016/j.rmed.2017.11.007Van Der Ent, C.K., Hoekstra, H. and Rijkers, G.T. (2007) Suc-cessful Treatment of Allergic Bronchopulmonary Aspergillosis with Recombinant Anti-IgE Antibody. Thorax, 62, 276-277. <br>https://doi.org/10.1136/thx.2004.035519Voskamp, A.L., Gillman, A., Symons, K., et al. (2015) Clinical Efficacy and Immunologic Effects of Omalizumab in Allergic Bronchopulmonary Aspergillosis. The Journal of Allergy and Clinical Immunology: In Practice, 3, 192-199.
<br>https://doi.org/10.1016/j.jaip.2014.12.008Wong, R., Wong, M., Robinson, P.D. and Fitzgerald, D.A. (2013) Omalizumab in the Management of Steroid Dependent Allergic Bronchopulmonary Aspergillosis (ABPA) Complicating Cystic Fibrosis. Paediatric Respiratory Reviews, 14, 22-24. <br>https://doi.org/10.1016/j.prrv.2012.11.004Agarwal, R., Muthu, V., et al. (2022) Allergic Bronchopulmonary Aspergillosis. Clinics in Chest Medicine, 43, 99-125.
<br>https://doi.org/10.1016/j.ccm.2021.12.002韩爽, 李远辉, 张健惠, 姚孟英. 78例变应性支气管肺曲霉病住院患者临床特征分析[J]. 中国实用医刊, 2021, 48(4): 1-3.Agarwal, R., Khan, A., Garg, M., Aggarwal, A.N. and Gupta, D. (2012) Chest Radiographic and Computed Tomographic Manifestations in Allergic Bronchopulmonary Aspergillosis. World Journal of Radiology, 4, 141-150.
<br>https://doi.org/10.4329/wjr.v4.i4.141张龙举, 李竹, 刘晓丽. 变态反应性支气管肺曲菌病244例临床荟萃分析[J]. 中国全科医学, 2019, 22(23): 2880-2884.Okayama, Y., Matsumoto, H., Odajima, H., et al. (2020) Roles of Omalizumab in Various Allergic Diseases. Allergology International, 69, 167-177. <br>https://doi.org/10.1016/j.alit.2020.01.004